Summary – The New York Yankees’ recent acquisition of pitcher Carlos Rodón has turned into a costly setback. Signed for $125 million, Rodón’s persistent injuries have prevented him from making a significant impact, exacerbating the team’s existing challenges.
Yankees’ $125 Million Gamble on Carlos Rodón Backfires Amid Injury Crisis
The New York Yankees’ aggressive offseason move to bolster their pitching rotation by signing left-hander Carlos Rodón to a six-year, $125 million contract has unraveled into a significant predicament. Rodón’s tenure with the Yankees has been marred by injuries, preventing him from delivering the elite performance the team had anticipated.
Rodón began the 2023 season on the injured list due to a muscle strain in his left forearm, with his recovery further delayed by a back injury. He was activated on July 7, 2023, but struggled upon his return. In his final start of the season on September 29, Rodón allowed eight runs without recording an out, concluding the season with a 3-8 record and a 6.85 ERA over 14 starts.
This setback compounds the Yankees’ existing injury woes. Ace pitcher Gerrit Cole is sidelined for the entire 2025 season following Tommy John surgery, a procedure necessitated by the increasing emphasis on pitching velocity, which has been linked to a surge in elbow injuries among pitchers. Additionally, outfielder Giancarlo Stanton is dealing with chronic calf issues alongside significant elbow pain, casting doubt on his availability for the upcoming season. These developments have significantly dampened fan confidence in the team’s prospects for the season. Many now view division rivals, such as the Baltimore Orioles, as the new favorites to clinch the American League East title. The Yankees’ management faces mounting pressure to address these challenges and reassess their strategies to navigate the season effectively.
